A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting Conditions

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG; Drug: NIRAVAM TM 2 mg orally disintegrating tablets, single dose

• Registration Number: NCT01188031
• Lead Sponsor: Actavis Inc.

Brief Summary

This study compared the relative bioavailability (rate and extent ofbsorption) of Alprazolam Orally Disintegrating Tablets, 2.0 mg by Purepac Pharmaceutical Co. with that of Niravam' 2 mg Orally Disintegrating Tablets manufactured for Schwarz Pharma, Inc. (by Cima Labs Inc.®)following a single, oral dose (I x 2 mg disintegrating tablet) in healthy adult volunteers administered under fasting conditions.

Detailed Description

Study Type: Interventional Study Design: This was a single-center, randomized, two-way crossover study conducted under fasting conditions Official Title: A Relative Bioavailability Study of 2 mg Alprazolam Oral Disintegrating Tablets under Fasting Conditions

Further study details as provided by Actavis Elizabeth LLC:

Primary Outcome Measures:

Rate and Extend of Absorption

Study Timeline

• Study Start: 2006-06
• Primary Completion: 2006-07
• Study Completion: 2006-07
• Status Verified: 2010-08
• Study First Submitted: 2010-08-23
• Study First Submitted QC: 2010-08-23
• Last Update Submitted: 2010-08-23
• Study First Posted: 2010-08-25
• Last Update Posted: 2010-08-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Subjects who met the following criteria were included in the study.

1. Volunteers who were informed of the nature of the study and who read, reviewed, and signed the informed consent prior to Period I dosing.
2. Volunteers who completed the screening process within 28 days prior to Period I dosing.
3. Volunteers who were healthy adult men and women 18 years of age or older at the time of dosing.
4. Volunteers who had a body mass index (BMI) between 18-32 kg/nr', inclusive, and weighed at least 110 lbs.
5. Volunteers who were healthy as documented by the medical history, physical examination (including but may not be limited to an evaluation of the cardiovascular, gastrointestinal, respiratory and central nervous systems), vital sign assessments, 12-lead electrocardiogram (ECG), clinical laboratory assessments, and by general observations. Any abnormalities/deviations form the normal range that were considered clinically relevant by the study physician and investigator were evaluated for individual cases, documented in study files, and agreed upon by both the study physician and investigator prior to enrolling the volunteer in this study and for continued enrollment.
6. Female volunteers ofpostmenopausal (no menses) status for at least 1 year and has a serum FSH level 2: 30 mlU/mL or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy.)

Exclusion Criteria

Subjects who met any ofthe following criteria were excluded from the study.

1. Volunteers who reported receiving any investigational drug within 28 days prior to Period I dosing.
2. Volunteers who reported any presence or history of a clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric disease as determined by the clinical investigator(s).
3. Volunteers whose clinical laboratory test values outside the accepted reference range and, when confirmed on re-examination, were deemed clinically significant.
4. Volunteers who demonstrated a reactive screen for hepatitis B surface antigen, hepatitis C antibody, or HIV antibody.
5. Volunteers who reported a history of allergic response(s) to alprazolam or related drugs.
6. Volunteers who reported the use of any systemic prescription medication in the 14 days prior to Period I dosing.
7. Volunteers who reported the use of any drug known to induce or inhibit hepatic drug metabolism in the 28 days prior to Period I dosing.
8. Volunteers who reported a history ofclinically significant allergies including drug allergies.
9. Volunteers who reported a clinically significant illness during the 4 weeks prior to Period I dosing (as determined by the clinical investigators).
10. Volunteers who reported a history of drug or alcohol abuse addiction or abuse within the past year.
11. Volunteers who demonstrated a positive drug abuse screen for this study prior to Period I dose administration.
12. Volunteers who currently used tobacco products.
13. Volunteers who reported donating greater than 150 mL ofblood within 28 days prior to Period I dosing. All subjects were advised not to donate blood for four weeks after completing the study.
14. Volunteers who donated plasma (e.g. plasmapheresis) within 14 days prior to Period I dosing. All subjects were advised not to donate plasma for four weeks after completing the study
15. Volunteers who demonstrated a positive pregnancy screen (females only).
16. Volunteers who were currently pregnant or breastfeeding (females only).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
ALPRAZOLAM ORALLY DISINTEGRATING TABLETS	ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG	ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG, single dose
NIRAVAM TM	NIRAVAM TM 2 mg orally disintegrating tablets, single dose	NIRAVAM TM 2 mg orally disintegrating tablets, single dose

Primary Outcome Measures

Name	Time	Method
Rate and Extend of Absorption	72hr

Trial Locations

Locations (1)

PRACS Institute, Ltd.; 🇺🇸 Fargo, North Dakota, United States